{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Return to MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
  • Sign In
  • Home
  • Live
  • On-Demand
  • RSS/Grand Rounds
  • Non-Accredited
  • About
  • Contact Us
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

MD Anderson workforce members:  Select "MD ANDERSON LOGIN" and enter your MD Anderson email address and password.

Guests (all other than MD Anderson workforce members): Select "GUEST LOGIN" and enter your email address and password.

MD ANDERSON LOGIN
GUEST LOGIN
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • AA
  • AAS
  • ADN
  • BA
  • BS
  • BSN
  • DDS
  • DMD
  • DMin
  • DNP
  • DO
  • DrPH
  • DVM
  • DVM,PhD
  • EdD
  • JD
  • MA
  • MBA
  • MBBS
  • MBBS,MD
  • MD
  • MD, MBA
  • MD, MPH
  • MD, PhD
  • MDiv
  • MEd
  • MHA
  • MPA
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • Other
  • PharmD
  • PharmD, PhD
  • PhD
  • PsyD
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

20th Oncology Updates: Advances and Controversies


LIVESurgeonsSurgical OncologyOncology Updates
20th Oncology Updates: Advances and Controversies Banner

  • Overview
  • Faculty
  • Schedule
  • Brochure
  • Hotel
  • Exhibitors
Add to Calendar 20th Oncology Updates: Advances and Controversies 1/12/2024 7:00:00 AM 1/15/2024 10:00:00 AM America/Chicago For More Details: https://mdanderson.cloud-cme.com/OnologyUpdates2024 Description: The treatment of solid tumors continues to evolve and clinicians must stay abreast of the current information and recent therapeutic advances. Many tumor types require multidisciplinary treatment; many therapies previously studied only in advanced and metastatic settings are now applied in early curative stages as well. Healthcare professionals who care for cancer patients in different stages of disease need t... Steamboat Grand Hotel false MM/DD/YYYY


Date & Location
Friday, January 12, 2024, 7:00 AM - Monday, January 15, 2024, 10:00 AM, Steamboat Grand Hotel, Steamboat Springs, CO

Target Audience
Specialties - Medical Oncology
Professions - Nurse - APRN, Other, Physician (MD or DO), Physician Associate

Credits
AMA PRA Category 1 Credits™ (19.50 hours), AAPA Category 1 CME (19.50 hours), ABS CC (19.50 hours), Medical Ethics/Professional Responsibility (1.50 hours), Non-Physician Attendance (19.50 hours)

Overview
The treatment of solid tumors continues to evolve and clinicians must stay abreast of the current information and recent therapeutic advances. Many tumor types require multidisciplinary treatment; many therapies previously studied only in advanced and metastatic settings are now applied in early curative stages as well. Healthcare professionals who care for cancer patients in different stages of disease need to understand the basis for these therapies. Additionally, HCPs must apply the preclinical and clinical data supporting the development and integration of these new therapies into their clinical practice. This educational conference will interactively address current management controversies, updates, and novel therapies for multiple tumor types. It will bring together experts from multiple disciplines involved in the treatment of various solid tumors. The expected outcome is the further integration of new cancer care developments into the clinical practice of surgeons, medical oncologists, radiation oncologists, and allied healthcare professionals. This conference is designed to empower these professionals in providing the best possible care for cancer patients.

Objectives
At the conclusion of this activity, learners will be able to:

  1. Utilize an appropriate sequence for surgical, radiation and chemotherapeutic intervention into the treatment of head and neck cancer, gastrointestinal malignancies, melanoma, lung cancer, breast cancer, gynecologic cancer, and genitourinary cancers.
  2. Describe and apply an optimal treatment approach when given patient scenarios representing a range of disease stages, clinical presentations and comorbidities.
  3. Incorporate preventive, screening and symptom control modalities in oncology care.
  4. Identify patients who will appropriately benefit from novel therapies in the treatment of solid tumors.
  5. Utilize the different surgical, radiation, and systemic treatments including immunotherapies and molecular-targeted therapies for cancers at varying stages of disease.

Registration
Registration on-site is available.

On-site registration for the 20th Annual Oncology Update: Advances and Controversies, will open at 6:30 am on Friday, January 12, 2024, and the conference will begin at 7:00 am.  The conference will adjourn at 8:15 pm on Monday, January 15, 2024.  Advanced registration is encouraged as space and materials are limited.  Please see registration form for applicable fees.

Advanced registration is encouraged. The deadline for advanced registration is January 3, 2024.

Fees:

REGISTRATION CATEGORY BEFORE
Jan. 3

AFTER
Jan. 3 
 Non MD Anderson Physicians/Scientists (MD, PhD)  $650 $700 
 MD Anderson Physician/Scientists (MD, PhD)  $400 $475
 Other Healthcare Professionals  $300 $375
 Guest Ticket (meals only)  $200 $250


We accept the following forms of payment:
  •Credit Cards (MasterCard, VISA, and American Express)
  •Check (Payable to The University of Texas MD Anderson Cancer Center; through U.S. banks only)

Mail checks to:
   Continuing Professional Education (CPE) – Unit 1781
   The University of Texas MD Anderson Cancer Center
   P.O. Box 301407
   Houston, Texas 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on your profile during the process. 

Telephone registrations are not accepted.

Refund/Cancellation Policy
The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 3, 2024.  No refunds will be granted after this date.  The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. 

The Department of Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of the CPE is limited to the registration fee. CPE will refund the full registration fee. 

CPE reserves the right to limit the number of participants in an activity and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

Special Assistance
For additional information or Special Assistance, contact CPE at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected]


Evaluation
A course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status.  Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. 

Accreditation

Accreditation
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 19.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.50 credit(s) of education in medical ethics and/or professional responsibility.

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 19.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.



Additional Information

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 


ACCOMMODATION

THE STEAMBOAT GRAND HOTEL
A block of rooms has been reserved for conference attendees at the Steamboat Grand Hotel, 2300 Mt. Werner Circle, Steamboat Springs, CO 80487

Reservations Phone: 877-269-2628.  Early hotel reservation is suggested.

The hotel phone number is 877-269-2628.

When you make reservations, be sure to mention the MD Anderson Cancer Center 2024 to be assured of receiving the special meeting rate.

Reservations and deposits received after December 12, 2023, will be confirmed if space is available and at currently published hotel guest room rates
Reservations Link:
https://group.steamboatgrand.com/v2/lodging-offers/promo-code?package=73181&code=MDAN24

Room Deposit: rooms are guaranteed 30 days prior to arrival by taking a full deposit of the entire stay. Upon the taking of the deposit all reservations are unchangeable.  If cancelled the deposit is non-refundable.

Room Tax and Fees: taxes are 20.4% of the room cost, and resort fee is 7% (plus 20.4% tax) currently totaling 28.828%. Taxes and resort fees are per room, per night, and are subject to change without notice. 

Ski Rentals/Lift Ticket Discounts:
Be sure to secure your tickets by calling central reservations: 877-269-2628.

Additional Hotels - Click on each property below for more information:

 
Ptarmigan Inn / Gravity Haus

Sheraton

West Condos

For more options, use the Steamboat.com link below to browse local lodging by neighborhood. The Steamboat Grand is in the "Base Area" neighborhood, so selecting the BASE AREA as the location will show the closest properties to The Grand!

Steamboat.com



The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.



Mitigation of Relevant Financial Relationships


The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Eric Gagneaux
Continuing Education Planner
MD Anderson Cancer Center
Activity Administrator
Non-Clinical Exception
Merrick I Ross, MD, FACS
Professor of Surgery
UT MD Anderson Cancer Center
Course Director, Faculty
Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Honoraria-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)
Thomas Aloia, MD, MPH
SVP, CMO
Ascension Health
Faculty
Nothing to disclose
Rodabe N. Amaria, MD
Associate Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Grant or research support-Obsidian|Grant or research support-OnKure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended)
Ana Aparicio, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Honoraria-Amgen Inc. (Relationship has ended)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Sanofi US|Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Daiichi Sankyo, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Biotech, Inc.|Honoraria-AstraZeneca US (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc.
Autumn Atkinson, MD
UTHealth
Faculty
Advisor-Novartis Pharmaceuticals Corporation (Relationship has ended)
Brian Badgwell, MD
Professor of Surgery
MD Anderson Cancer Center
Faculty
Nothing to disclose
Charles M Balch, MD
Research Professor
MDACC
Faculty
Nothing to disclose
Kelly K Bree, MD
Assistant Professor
MD Anderson Cancer Center
Faculty
Nothing to disclose
Thomas A Buchholz, MD
Scripps MD Anderson Cancer Center
Faculty
Nothing to disclose
Matthew T Campbell, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Advisor-Eisai, Inc. (Relationship has ended)|Advisor-Pfizer Inc. (Relationship has ended)|Consulting Fee-Exelixis (Relationship has ended)|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended)|Grant or research support-Seattle Genetics, Inc.|Advisor-AXDev (Relationship has ended)|Grant or research support-Exelixis|Grant or research support-Pfizer Inc.|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Aravive|Grant or research support-AstraZeneca US|Grant or research support-ApricityHealth (Relationship has ended)
Abigail Caudle, MD, ABS
MD Anderson Cancer Center
Faculty
Nothing to disclose
Brian F Chapin, MD
Professor
MD Anderson Cancer Center
Faculty
Advisor-Johnson & Johnson (any division)|Grant or research support-Regeneron Pharmaceuticals, Inc.|Advisor-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Advisor-Pfizer Inc.|Advisor-Janssen Biotech, Inc.
Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor
Associate Professor
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc.|Advisor-Genomic Health, Inc. (Relationship has ended)
Ana Ciurea, MD
MD Anderson Cancer Center
Faculty
Nothing to disclose
Lorenzo Cohen, PhD
Professor and Director
MD Anderson Cancer Center
Faculty
Nothing to disclose
Anh Q Dang, MD
Dr.
University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
John W Davis, MD, FACS
Professor
MD Anderson Cancer Center
Faculty
Advisor-Intuitive Surgical, Inc. (Relationship has ended)|Grant or research support-Janssen Biotech, Inc.
Keith Delman, MD
Dr.
Emory University SOM
Faculty
Nothing to disclose
Colin Dinney, MD
Professor and Chairman
UT MD Anderson Cancer Center
Faculty
Consulting Fee-AstraZeneca US|Consulting Fee-CG Oncology|Grant or research support-NHI/NCI|Other: Drug-Nadofaragene firadenovec
Steven Frank, MD
Professor
MD Anderson Cancer Center
Faculty
Consulting Fee-Boston Scientific Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-C4 Imaging|Grant or research support-Hitachi Medical Systems America, Inc.|Grant or research support-Affirmed Pharma|Honoraria-IBA
Michael Frumovitz, MD, MPH
Professor and Chief Patient Experience Officer
MD Anderson
Faculty
Consulting Fee-Stryker (any division)|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-AkesoBio|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended)
Jeffrey Gershenwald, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)
Don L Gibbons, MD, PhD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Advisor-Lilly USA, LLC (Relationship has ended)|Grant or research support-NGM Biopharmaceuticals (Relationship has ended)|Grant or research support-Boehringer Ingelheim|Advisor-Menarini Ricerche|Advisor-Onconova (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-Sanofi US
Isabella Glitza Oliva, MD, PhD
Associate Professor
UT MD Anderson Cancer Center
Faculty
Consulting Fee-Novartis Pharmaceuticals Corporation|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Pfizer Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division)
Justin R. Gregg, MD
Assistant Professor
UT MD Anderson Cancer Center
Faculty
Advisor-Bayer HealthCare Pharmaceuticals, Inc.
Wayne Hofstetter, MD
Professor
MD Anderson Cancer Center
Faculty
Nothing to disclose
Kelly K. Hunt, MD
Professor
MD Anderson Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Armada Health|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Grant or research support-Lilly USA, LLC|Grant or research support-Cairn Surgical|Grant or research support-Lumicell
Rosa F Hwang, MD, FACS
Professor, Breast Surgical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Intuitive Surgical, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Stellanova Therapeutics
John Hyngstrom, MD
Associate Professor
Huntsman Cancer Institute
Faculty
Grant or research support-Amgen Inc.|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Lyell|Grant or research support-Natera|Grant or research support-Skyline|Grant or research support-Philogen|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-Iovance|Grant or research support-Morphogenesis|Grant or research support-Takara (Relationship has ended)
Matthew H Katz, MD
Professor, Surgical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Michael P Kim, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Consulting Fee-PanTher Therapeutics|Consulting Fee-Olympus Corporation of the Americas
Jennifer K. Litton, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Honoraria-UpToDate|Grant or research support-Pfizer Inc. (Relationship has ended)|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants (Relationship has ended)|Grant or research support-Zenith (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-EMD Serono Inc. (Relationship has ended)|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-Genentech, Inc. (Relationship has ended)|Speakers Bureau-Clinical Care Options|Speakers Bureau-Medscape|Speakers Bureau-Physician's Education Resource|Speakers Bureau-Prime Oncology (Relationship has ended)|Speakers Bureau-Medpage|Speakers Bureau-WebMD|Royalties or Patent Beneficiary-Certis|Speakers Bureau-@tumorboardtues (Relationship has ended)
Ethan B Ludmir, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Paul F Mansfield, MD
Professor of Surgical Oncology
UT MD Anderson Cancer Center
Faculty
Stocks or stock options, excluding diversified mutual funds-Amgen Inc.|Stocks or stock options, excluding diversified mutual funds-Stryker (any division)
Jennifer McQuade, MD
Assistant Professor
MD Anderson Cancer Center
Faculty
Honoraria-Merck Sharp & Dohme Corp. (any division)
Reza Mehran, MD, FACS
Professor
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Funda Meric-Bernstam, MD
Chair, Invest. Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-AstraZeneca US|Consulting Fee-Biovica (Relationship has ended)|Consulting Fee-Black Diamond (Relationship has ended)|Consulting Fee-Eisai, Inc. (Relationship has ended)|Consulting Fee-F. Hoffmann La Roche (Relationship has ended)|Consulting Fee-Karyopharm Therapeutics (Relationship has ended)|Consulting Fee-Lengo Therapeutics (Relationship has ended)|Consulting Fee-LOXO-Oncology (Relationship has ended)|Consulting Fee-OnCusp Therapeutics (Relationship has ended)|Consulting Fee-Seattle Genetics, Inc.|Consulting Fee-Tallac Therapeutics (Relationship has ended)|Consulting Fee-Zentalis (Relationship has ended)|Consulting Fee-Zymeworks|Grant or research support-Aileron Therapeutics|Grant or research support-AstraZeneca US|Grant or research support-Bayer HealthCare Pharmaceuticals, Inc.|Grant or research support-Calithera|Grant or research support-CytomX Therapeutics|Grant or research support-Curis|Grant or research support-Daiichi Sankyo, Inc.|Grant or research support-Debiopharm|Grant or research support-eFFECTOR Therapeutics|Grant or research support-Genentech, Inc.|Grant or research support-Klus Pharma|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Puma Pharmaceuticals|Grant or research support-Taiho Oncology, Inc.|Consulting Fee-GT Apeiron (Relationship has ended)|Consulting Fee-Menarini|Consulting Fee-Ecor1|Consulting Fee-Calibr (a division of Scripps Research),|Consulting Fee-LegoChem Bio|Consulting Fee-Theratechnologies|Honoraria-Dava Oncology (Relationship has ended)|Other: Travel Reimbursement-Dava Oncology (Relationship has ended)|Consulting Fee-Protai
Lavinia P Middleton, MD
Professor of Pathology
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Neema Navai, MD
Associate Prof and Deputy Chair
MD Anderson Cancer Center
Faculty
Royalties or Patent Beneficiary-Allergan, Inc.
Timothy Newhook, MD
MD Anderson Cancer Center
Faculty
Consulting Fee-Intuitive Surgical, Inc. (Relationship has ended)
Quynh-Nhu Nguyen, MD
Associate Professor
University of Texas, M.D. Anderson Cancer Center
Faculty
Nothing to disclose
Anisha Patel, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Grant or research support-Pfizer Inc. (Relationship has ended)|Grant or research support-OnQuality|Grant or research support-Lutris|Paid consultant-Deciphera|Paid consultant-Novartis Pharmaceuticals Corporation (Relationship has ended)|Paid consultant-Repare Therapeutics|Paid consultant-Janssen Biotech, Inc.|Grant or research support-Hoth|Paid consultant-Asymmetric|Paid consultant-Lutris
Sapna Patel, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Foghorn Therapeutics|Grant or research support-Ideaya|Grant or research support-InxMed|Grant or research support-Lyvgen Biopharma|Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Provectus Biopharmaceuticals|Grant or research support-Seattle Genetics, Inc.|Grant or research support-Syntrix Bio|Grant or research support-TriSalus Life Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Delcath (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ideaya|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-OncoSec (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Replimune (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-TriSalus Life Sciences|Speakers Bureau-Bristol-Myers Squibb Company|Speakers Bureau-Merck Sharp & Dohme Corp. (any division)
George Perkins, MD
Professor and Chief Medical Officer Faculty Practice
The University of Texas M D Anderson Cancer Center
Faculty
Nothing to disclose
Peter Pisters, MD
President, Presidents Office
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Victor G Prieto, MD, PhD, USCAP, ASDP, ISDP, CAP, ASCP
Chair and Professor
MD Anderson Cancer Center
Faculty
Consulting Fee-Myriad (Relationship has ended)|Consulting Fee-Orlucent|Consulting Fee-Castle Biosciences, Inc.
Jose Alejandro Rauh-Hain, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Schlesinger Group|Consulting Fee-Guidepoint
Maria C Russell, MD
Dr. Maria Russell
Emory
Faculty
Nothing to disclose
Aysegul Sahin, MD
Professor
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Kathleen M Schmeler, MD
Professor, Gynecologic Oncology & Reproductive Medicine
The University of MD Anderson Cancer Center
Faculty
Nothing to disclose
Sumit K Subudhi, MD, PhD
Associate Professor
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Stephen G Swisher, MD
Division Head
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Hop Sanderson Tran Cao, MD, FACS
Associate Professor - Surgical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Intuitive Surgical, Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division)
Ching-Wei D Tzeng, MD
Associate Professor
University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-PanTher|Consulting Fee-Iota
Roi Weiser, MD
Dr.
MD Anderson
Faculty
Nothing to disclose
Robert A. Wolff, MD
Professor, GI Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Brian K Bednarski, MD
Associate Professor
MD Anderson Cancer Center
Faculty, Other Planning Committee Member
Nothing to disclose
Alyssa C Amin, PA, PA-C
Physician Assistant
MD Anderson Cancer Center
Other Planning Committee Member
Nothing to disclose
Rae B Reynolds, PhD
Mgr, Adv Practice Providers
MD Anderson Cancer Center
Other Planning Committee Member
Nothing to disclose
Cynthia Scott, BS
Office Manager
UT MD Anderson Cancer Center
Other Planning Committee Member
Non-Clinical Exception

Friday, January 12, 2024
Welcome and Opening Remarks
7:00AM - 7:10AM
Merrick I Ross, MD, FACS
 
Session I: Efforts to Support and Improve Patient and Provider Experience

Moderator: Merrick Ross
Diagnosing and Managing Immune-Related Treatment Toxicities: Overview of Grade IV Events
7:10AM - 7:30AM
Isabella Glitza Oliva, MD, PhD
Avoiding Perioperative Adrenal Crisis
7:30AM - 7:42AM
Roi Weiser, MD
Dermatologic Toxicities
7:42AM - 7:57AM
Anisha Patel, MD
Interactions Between Microbiome and Responses to Immunotherapy
7:57AM - 8:12AM
Jennifer McQuade, MD
Pre-Habilitation for High-Risk Surgery
8:12AM - 8:24AM
Anh Q Dang, MD
*Burnout and Personal Wellness Amongst Surgeons
8:24AM - 8:44AM
Charles M Balch, MD
*Patient Experience from the Perspective of a Cancer Care Provider
8:44AM - 9:04AM
Michael Frumovitz, MD, MPH
Q & A
9:04AM - 9:30AM
Break
9:30AM - 4:00PM
 
Session II: The Best of 2023: Practice Changing Trials / Results

Moderator: Merrick Ross
Breast Cancer
4:00PM - 4:18PM
Jennifer K. Litton, MD
Melanoma
4:18PM - 4:36PM
Sapna Patel, MD
Urological Oncology
4:36PM - 4:54PM
Matthew T Campbell, MD
Non-Small Cell Lung Cancer
4:54PM - 5:12PM
Don L Gibbons, MD, PhD
Head and Neck Squamous Cell Carcinoma
5:12PM - 5:30PM
Steven Frank, MD
Q & A
5:30PM - 5:45PM
 
Session III: "Biomarker Driven Risk Stratification, Treatment, and Prophylaxis: Evidence for Clinical Utility Their Cancer Treatment Journey"

Moderator: Funda Meric-Bernstam
Efforts by the AJCC to Incorporate Biomarkers into Staging Criteria
5:50PM - 6:05PM
Jeffrey Gershenwald, MD
Biomarker Directed Conjugate Therapy and Promising Actional Targets
6:05PM - 6:25PM
Funda Meric-Bernstam, MD
Circulating Tumor DNA in Colon Cancer
6:25PM - 6:37PM
Timothy Newhook, MD
CDH-1 Prophylactic Gastric Surgery
6:37PM - 6:52PM
Paul F Mansfield, MD
PiK3CA Mutation Directed Therapy
6:52PM - 7:07PM
Autumn Atkinson, MD
*Keynote Presentation 1: Is a Value-Based Funding Model Realistic for Oncology Care?
7:07PM - 7:27PM
Thomas Aloia, MD, MPH
*Keynote Presentation 2: Integrative Medicine Support: Is There Evidence for Improved Outcomes?
7:27PM - 7:42PM
Lorenzo Cohen, PhD
Welcome Reception
8:00PM - 10:00PM
Saturday, January 13, 2024
 
Session IV: Thoracic Oncology

Moderator: Stephen Swisher
Treatment of Primary NSCLC with Curative intent: How to select between Lobar vs Sublobar Resection vs SBRT
7:00AM - 7:20AM
Stephen G Swisher, MD
Recent Advances in Perioperative/Neoadjuvant Therapy for Resectable NSCLC
7:20AM - 7:40AM
Don L Gibbons, MD, PhD
Radiation Therapy in the Treatment of Oligometastatic Disease to the Lung
7:40AM - 7:55AM
Quynh-Nhu Nguyen, MD
Any Progress Made in the Treatment of Pleural Mesothelioma
7:55AM - 8:10AM
Reza Mehran, MD, FACS
Evolving Management of Locally Advanced Esophageal Cancer: Successes and Failures
8:10AM - 8:25AM
Wayne Hofstetter, MD
Panel Q and A and Case Presentations
8:25AM - 9:30AM

All Speakers
Break
9:30AM - 4:30PM
 
Session V: GI and Hepatobiliary Oncology

Moderator: Robert Wolff
Advances in the Multi-Disciplinary Management of Advanced Gastric Cancer
4:30PM - 4:45PM
Brian Badgwell, MD
Critical Assessment of HIPEC: What Goals Have Been Achieved?
4:45PM - 5:00PM
Maria C Russell, MD
Advances in the Multi-Modality Management of Resectable Pancreas Cancer
5:00PM - 5:20PM
Michael P Kim, MD
Advances in the Treatment of Hepatic Malignancies: Neoadjuvant Therapy for Cholangiocarcinoma
5:20PM - 5:32PM
Hop Sanderson Tran Cao, MD, FACS
Advances in the Treatment of Hepatic Malignancies: Definitive Ablative Therapy for Primary Liver Tumors
5:32PM - 5:47PM
Ethan B Ludmir, MD
Advances in the Treatment of Hepatic Malignancies: Innovations to Improve the Safety and Outcomes of Hepatic Resections
5:47PM - 5:59PM
Ching-Wei D Tzeng, MD
Paradigm Shift in the Multi-modality Treatment of Locally Advanced Rectal Cancer: Results of PROSPECT Trial
5:59PM - 6:14PM
Brian K Bednarski, MD
Special MD Anderson Presidential Address: Development of a State-of-the-Art Integrated Multidisciplinary Colon and Rectum Center
6:14PM - 6:29PM
Peter Pisters, MD
Panel Q and A and Case Presentations:
6:29PM - 7:30PM

All Speakers + Newhook
Sunday, January 14, 2024
 
Session VI: Urology

Moderator: Brian Chapin
Proton Therapy or Prostate Cancer- Update of Clinical Outcomes
7:00AM - 7:12AM
Steven Frank, MD
Radical Prostatectomy: Extreme Indications, Solutions, and Knowing when to Punt
7:12AM - 7:24AM
John W Davis, MD, FACS
Obesity, Dietary Quality and Localized Prostate Cancer Progression
7:24AM - 7:36AM
Justin R. Gregg, MD
Female Sexual Health in the Management of Bladder Cancer
7:36AM - 7:48AM
Kelly K Bree, MD
The Development of Adstiladrin for NMIBC
7:48AM - 8:00AM
Colin Dinney, MD
Great Debate: Cytoreductive Nephrectomy in the Era of Immunotherapy
8:00AM - 8:16AM
Colin Dinney, MD
Neema Navai, MD

Pros: Colin Dinney

Cons: Neema Navai


Panel Q&A and Christopher Wood Memorial Case Presentations
8:16AM - 9:30AM
Brian F Chapin, MD

Panelist: All Speakers + Aparicio, and Campbell
Break
9:30AM - 4:30PM
 
Session VII: Breast and Gynecological Oncology

Moderator: Kelly Hunt
Targeted Axillary Dissection after Neoadjuvant Therapy: Can We Finally Conclude That This is the Standard of Care?
4:30PM - 4:45PM
Abigail Caudle, MD, ABS
What Does the Future Look Like for Robotic Skin/Nipple Sparing Mastectomy
4:45PM - 5:00PM
Rosa F Hwang, MD, FACS
Radiation Therapy Controversies: Trends for De-escalation
5:00PM - 5:20PM
Thomas A Buchholz, MD
Expanding the Utility of HER-2 Status in Clinical Decision-Making Pathology Perspective
5:20PM - 5:32PM
Aysegul Sahin, MD
Expanding the Utility of HER-2 Status in Clinical Decision-Making: Clinical Management Perspective
5:32PM - 5:47PM
Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor
What is on the Horizon for Triple-Negative and Inflammatory Breast Cancer
5:47PM - 6:02PM
Jennifer K. Litton, MD
Debulking Surgery for Ovarian Cancer: Open vs Laparoscopic
6:02PM - 6:17PM
Jose Alejandro Rauh-Hain, MD
Panel Q & A and Case Presentations: Kelly Hunt and Rosa Hwang
6:17PM - 7:30PM
Rosa F Hwang, MD, FACS
Kelly K. Hunt, MD

Panelist: All Speakers + Middleton, Schmeler, Meric-Bernstam, and Perkins
Monday, January 15, 2024
 
Session VIII: Cutaneous Oncology

Moderator: Merrick Ross
De-escalation of Surgery for High-risk Stage II and Advanced Stage III Melanoma: Ready for Prime Time?
7:00AM - 7:20AM
John Hyngstrom, MD
Pathological Response to Neoadjuvant Therapy: Definitions and Clinical Relevance
7:20AM - 7:35AM
Victor G Prieto, MD, PhD, USCAP, ASDP, ISDP, CAP, ASCP
Update and Future Directions of Adjuvant Therapy for High-Risk Melanoma
7:35AM - 7:50AM
Merrick I Ross, MD, FACS
Tumor Infiltrating Lymphocyte Therapy for Disseminated Melanoma: Patient Selection and Novel Strategies
7:50AM - 8:05AM
Jennifer McQuade, MD
Targeted and Immunotherapy for Advanced Non-Melanoma Skin Cancer
8:05AM - 8:20AM
Keith Delman, MD
Panel Q & A Case Presentations
8:20AM - 9:30AM

All Speakers + Gershenwald, Glitza, and Ciurea
Conference Review and Closing Remarks
9:30AM - 10:00AM
Merrick I Ross, MD, FACS


Contact Us:
Cicely Simon
The University of Texas MD Anderson Cancer Center
7007 Bertner Avenue, Ste. 1MC16.2343
Unit 1781
Houston, TX 77030
Email: [email protected]


W9 Form

Exhibitor Packages

Exhibitor Package - 1 - Additional Badge Price: $500.00
Includes:
  • Number of Exhibitor Badges: 1

Deadline for order commitment is 1/5/2024 12:00:00 AM.

Exhibitor Package - Additional Badge (Post Registration) Price: $500.00
Includes:
  • Number of Exhibitor Badges: 1

Deadline for order commitment is 1/5/2024 12:00:00 AM.

Exhibitor Package - 2 - Additional Badges Price: $1000.00
Includes:
  • Number of Exhibitor Badges: 2

Deadline for order commitment is 12/23/2023 12:00:00 AM.

Exhibitor Package - 3 - Additional Badges Price: $1500.00
Includes:
  • Number of Exhibitor Badges: 3

Deadline for order commitment is 1/5/2024 12:00:00 AM.

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
 Privacy policies   

©2023 The University of Texas MD Anderson Cancer Center
Contact Us: [email protected]

See us on Facebook See us on Twitter See us on Linked In See us on Instagram